SCHEMBL904493

SCHEMBL904493

CC(C)(c1ccc(O)cc1)c1ccc(OCCO)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.60
SMN1; SMN2 Q16637 2/20 0.60
ESR1 P03372 3/20 0.57
ESR2 Q92731 3/20 0.57
AR P10275 2/20 0.57
HPGD P15428 2/20 0.57
TSHR P16473 2/20 0.57
SLC6A2 P23975 1/20 0.57
SLC6A4 P31645 1/20 0.57
HTR6 P50406 1/20 0.57
ESRRG P62508 1/20 0.57
SLC6A3 Q01959 1/20 0.57
HSD17B10 Q99714 1/20 0.57
ALDH1A1 P00352 4/20 0.50
KDM4E B2RXH2 4/20 0.49
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
POLB P06746 2/20 0.49
LMNA P02545 1/20 0.49
CYP19A1 P11511 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9818198 0.93 SMN1; SMN2 (0.68) CYP3A4SMN1; SMN2ARHPGDTSHR
SCHEMBL79031 0.93 SMN1; SMN2 (0.68) CYP3A4SMN1; SMN2ARHPGDTSHR
SCHEMBL7261016 0.91 CYP3A4 (0.55) CYP3A4SMN1; SMN2ESR1ESR2AR
SCHEMBL11176645 0.90 APP (0.51) CYP3A4SMN1; SMN2ESR1ESR2AR
SCHEMBL12516039 0.90 APP (0.51) CYP3A4SMN1; SMN2ESR1ESR2AR
SCHEMBL15890450 0.87 SMN1; SMN2 (0.62) CYP3A4SMN1; SMN2ARHPGDTSHR
1,3-Propanediol SCHEMBL17704098 0.87 SMN1; SMN2 (0.62) CYP3A4SMN1; SMN2ARHPGDTSHR
Di(Hydroxyethyl)Ether SCHEMBL9469009 0.87 SMN1; SMN2 (0.62) CYP3A4SMN1; SMN2ARHPGDTSHR
SCHEMBL9818138 0.87 SMN1; SMN2 (0.62) CYP3A4SMN1; SMN2ARHPGDTSHR
SCHEMBL5707301 0.87 SMN1; SMN2 (0.62) CYP3A4SMN1; SMN2ARHPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1834975-B1 Thermosetting poly(phenylene ether) SABIC INNOVATIVE PLASTICS IP (NL) 2011-05-11 EP claimed
US-10023698-B2 Curable benzoxazine compositions with improved thermal stability 3M INNOVATIVE PROPERTIES COMPANY (US) 2018-07-17 US disclosed
US-20170283558-A1 CURABLE BENZOXAZINE COMPOSITIONS WITH IMPROVED THERMAL STABILITY 3M INNOVATIVE PROPERTIES COMPANY 2017-10-05 US disclosed
US-20170260132-A1 OXIME SULFONATE DERIVATIVES BASF SE (DE) 2017-09-14 US disclosed
EP-2521707-B1 BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) 2017-06-14 EP disclosed
US-9388112-B2 Bisphenol derivatives and their use as androgen receptor activity modulators THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2016-07-12 US disclosed
US-9388112-B2 Bisphenol derivatives and their use as androgen receptor activity modulators THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2016-07-12 US disclosed
EP-2289968-B1 Polyester process XEROX CORP (US) 2016-04-27 EP disclosed
US-9310677-B2 Polymerizable composition comprising an oxime sulfonate as thermal curing agent BASF (DE) 2016-04-12 US disclosed
US-20160060214-A1 POLYMERIZABLE COMPOSITION COMPRISING AN OXIME SULFONATE AS THERMAL CURING AGENT BASF SE (DE) 2016-03-03 US disclosed
US-20110281124-A1 SOLUTION AND PROCESS FOR INCREASING THE SOLDERABILITY AND CORROSION RESISTANCE OF A METAL OR METAL ALLOY SURFACE ATOTECH USA, LLC 2011-11-17 US disclosed
WO-2011082487-A1 BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) 2011-07-14 WO disclosed
US-20110053079-A1 POLYESTER PROCESS XEROX CORPORATION (US) 2011-03-03 US disclosed
EP-2289968-A1 Polyester process Xerox Corporation (US) 2011-03-02 EP disclosed
EP-0545407-B1 Thermal dye transfer receiving element with polyester dye image-receiving layer EASTMAN KODAK CO (US) 1995-10-04 EP disclosed
US-5387571-A Polyester containing dicarboxylic acid derived units having alicyclic ring within two carbon atoms of each carboxyl group, diol derived units having aromatic ring not immediately adjacent each hydroxyl group or alicyclic ring EASTMAN KODAK COMPANY (US) 1995-02-07 US disclosed
US-5223335-A Melting linear aromatic oligomer having terminal aliphatic hydroxy group, bis/acylcaprolactam/, tetraalkoxytitanium catalyst; impregnating fibrous reinforcing material, heating to form thermoplastic copolymer matrix TEIJIN LIMITED (JP) 1993-06-29 US disclosed
EP-0545407-A1 Thermal dye transfer receiving element with polyester dye image-receiving layer EASTMAN KODAK COMPANY (US) 1993-06-09 EP disclosed
EP-0505139-A1 Fiber-reinforced composite material and process for the production thereof TEIJIN LIMITED (JP) 1992-09-23 EP disclosed
US-4756973-A Three-dimensional network structure layer forming resin containing spirooxazine compound and phenolic resin KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1988-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10023698-B2 Curable benzoxazine compositions with improved thermal stability BRWD1, CBX7, WIZ CYP3A4 1003/4885SMN1; SMN2 381/4885ESR1 3080/4885
US-20170260132-A1 OXIME SULFONATE DERIVATIVES CBR3, CBR1, C1R CYP3A4 35/4885SMN1; SMN2 3180/4885ESR1 631/4885
US-20170283558-A1 CURABLE BENZOXAZINE COMPOSITIONS WITH IMPROVED THERMAL STABILITY BRWD1, CBX7, WIZ CYP3A4 1003/4885SMN1; SMN2 381/4885ESR1 3080/4885
US-20160060214-A1 POLYMERIZABLE COMPOSITION COMPRISING AN OXIME SULFONATE AS THERMAL CURING AGENT SULT1E1, COX6B1, SULT1A1 CYP3A4 25/4885SMN1; SMN2 2191/4885ESR1 140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.